Laguna Hills, CA – According to filings with the U.S. Securities and Exchange Commission, Amberstone Biosciences is raising $12,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, George Wu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Amberstone Biosciences
At Amberstone Biosciences we discover transformative therapeutic antibodies through innovative technologies and creative partnerships to benefit patients with unmet medical needs. With a bold vision to pioneer a new wave of therapeutic breakthroughs, our team of dedicated and passionate scientists and entrepreneurs strive to discover transformative therapeutic antibodies through innovative technologies and creative partnerships to benefit patients with unmet medical needs.

To learn more about Amberstone Biosciences, visit http://www.amberstonebio.com/

Contact:
George Wu, Chief Executive Officer
949-269-7918
https://www.linkedin.com/in/george-wu-4818b724/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved